Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
Hematology Section, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
Bone Marrow Transplant. 2017 Sep;52(9):1225-1232. doi: 10.1038/bmt.2017.30. Epub 2017 Mar 20.
The discovery of T regulatory cells has been one of the most important advances in basic immunology and has opened the door to the development of innovative therapeutic strategies for improving the outcome of solid organ and hematopoietic stem cell transplantation. Basic immunology is rapidly elucidating the complex biology of these cells even though the difficulties in purifying or even expanding them in vitro represent a major limitation to the development of clinical studies. The clinical benefit potentially associated with this therapeutic approach remains to be demonstrated. Meanwhile, several drugs used for the treatment of hematologic malignancies or for other purposes have been shown to upregulate the number and function of Tregs in vivo. In the near future, both ex vivo or in vivo expanded T cells are likely to enter the therapeutic armamentarium of clinical transplantation.
T 调节细胞的发现是基础免疫学最重要的进展之一，为开发改善实体器官和造血干细胞移植结果的创新治疗策略开辟了道路。基础免疫学正在迅速阐明这些细胞的复杂生物学特性，尽管在体外纯化甚至扩增这些细胞的困难是临床研究发展的主要限制。这种治疗方法可能带来的临床益处仍有待证明。与此同时，一些用于治疗血液系统恶性肿瘤或其他用途的药物已被证明可在体内上调 Treg 的数量和功能。在不久的将来，体外或体内扩增的 T 细胞都有可能进入临床移植的治疗武器库。
